The biotech’s ceo, Kevin Sharer, just doesn’t get it.

Late Friday, he holds a hastily put together conference call to belatedly disclose that a clinical trial, which was halted in October and posted on the Internet a few weeks later, showed its top-selling Aranesp cancer drug may actually increase tumor growth. Why then? The Cancer Letter published an item that morning, prompting a negative reaction from a Wall Street analyst.

Amgen says the info was reported to the FDA in December. But what about everyone else? You know, patients, doctors, investors, the Securities and Exchange Commission? “It’s not ethical, not honest and not what scientific discourse is all about,” ‘Peter Eisenberg, a cancer doctor in Marin County, California, and a director of the American Society of Clinical Oncology, told Bloomberg News.

Ironically, Amgen execs are in a huff because the Tour of California, a big cycling event, recently boasted that its participants are tested for performance-enhancing drugs - with one exception, Amgen’s EPO, a blood booster that’s used to treat anemia in cancer patients. Amgen, you see, sponsors the event and a spokeswoman told The New York Times the biotech is outraged and disappointed.

In other words, Amgen demands accountability and transparency from others - but not its own executives. How convenient.